RxDoctor Payments Data

Christy Montegut, MD

Family Medicine · la Place, LANPI 1174571798

Payments from drug & device makers

$8,585in general payments, 2019–2025

Across 488 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$969
  • Johnson & Johnson$901
  • GSK$765
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$461
  • Kowa Pharmaceuticals America, Inc.$433
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$8,580100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,585 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,912
Medicare patients
83
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$88,106
MounjaroTirzepatide73$78,670
JanuviaSitagliptin Phosphate77$69,259
EliquisApixaban72$43,443
JardianceEmpagliflozin43$40,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$36,565
XareltoRivaroxaban51$35,025
FarxigaDapagliflozin Propanediol24$22,209
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen625$14,768
InvokanaCanagliflozin17$10,861
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen253$7,824
LinzessLinaclotide14$7,393
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,114
Diclofenac Sodium ErDiclofenac Sodium186$5,568
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$5,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$348$88,10682 claims
Lilly USA, LLCMounjaro$969$78,67073 claims
MerckJanuvia$95$69,25977 claims
Johnson & JohnsonXarelto, Invokana$901$45,88668 claims
PfizerEliquis$267$43,44372 claims
Boehringer IngelheimJardiance$302$40,52643 claims
GSKTrelegy Ellipta$765$36,56546 claims
AstraZenecaFarxiga, Symbicort$277$25,64639 claims
AbbVieLinzess$1,563$7,39314 claims
Sanofi-aventis U.S. LLCLantus$143$1,56815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in la Place

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →